A slide set displaying the primary results of TECOS, as presented at the ADA on Mon 8th June 2015, is freely-available for download via the link below.
The TECOS study group presented the primary results today to an audience of over 6,500 attendees at the 75th Annual Scientific Sessions of the American Diabetes Society in Boston, Massachusetts, US.
ABSTRACT
BACKGROUND....
The TECOS primary results will be presented at the 2015 ADA 75th Scientific Sessions in Boston, US, on the afternoon of Monday 8th June at 4:30 pm.
2012 was an exciting year for TECOS that saw the close of recruitment following randomisation of over 14,700 participants. Of the participating countries, 21 of 38 met or exceeded their recruitment targets....
[Read more...]
We are delighted to announce that more than 14,000 patients have now been recruited to the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) trial.
Investigators from across the globe joined the TECOS management team to celebrate reaching this milestone at the American Diabetes Association (ADA) conference in Philadelphia, USA on Saturday 9th June....
On 22nd March, the Oxford-based TECOS team hosted a European Investigators Meeting for a selection of European sites in Noordwijkerhout, Netherlands - a region known fondly as the "Dune and Bulb Region".
Representatives from many of our new European sites were also there, and along with those from numerous existing sites, got the opportunity to learn about the trial and share experiences....
On the 24 March 2011, the TECOS team arrived in Prague to host the initiation meeting for the new sites in Europe, Israel and South Africa.
The event covered academic issues as well as the operational management of TECOS....
The protocol amendment designed to reflect the real-world population; by permitting insulin use (with or without metformin) at baseline was approved in August by the Committee for Medicinal Products for Human Use (CHMP). The number of patients required to be taking pioglitazone at baseline has also been reduced from 2000 to 1000....
[Read more...]Since the first subject was enrolled in December 2008, TECOS has witnessed a number of study milestones. The majority of sites are now actively enrolling patients....
[Read more...]The Executive Committee for the Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) will accept ancillary study proposals for review. Ancillary studies may provide valuable information beyond that explored in the context of the main trial, and will promote continued academic interest in TECOS.
[Link]The TECOS poster entitled "Rationale & Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)" was presented on Sept 30th by Dr M. Angelyn Bethel at the European Association for the Study of Diabetes (EASD) international conference in Vienna.
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) launched in Europe in June and has recruited 30 participants to date from Hungary, Lithuania & Spain.
Centres in India, South Africa and Canada are now open and are expected to start recruiting shortly.
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) has been recruiting patients in the United States since December 2008 and with nearly 100 patients already randomised, TECOS is now about to begin recruitment across a number of countries around the world.
Since early 2009 the Duke Clinical Research Institute (DCRI) and the Diabetes Trials Unit, University of Oxford (DTU) have hosted a number of training days (Investigator Meetings) for new clinical sites in North America, India and Europe, and will be launching the trial in the Asia/Pacific regions over the Summer....